Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 18/20 | 0.50 |
| ▸ | HCRTR1 | O43613 | 16/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2878496 | 0.75 | HCRTR2 (0.53) | HCRTR2HCRTR1NR1I2ADRA2BKCNH2 | |
| SCHEMBL2858331 | 0.73 | HCRTR2 (0.61) | HCRTR2HCRTR1NR1I2ADRA2BKCNH2 | |
| SCHEMBL3090879 | 0.72 | HCRTR2 (0.51) | HCRTR2HCRTR1 | |
| SCHEMBL2858983 | 0.71 | HCRTR2 (0.70) | HCRTR2HCRTR1 | |
| SCHEMBL2878094 | 0.70 | HCRTR2 (0.52) | HCRTR2HCRTR1 | |
| SCHEMBL1819323 | 0.70 | HCRTR2 (0.72) | HCRTR2HCRTR1NR1I2ADRA2BKCNH2 | |
| SCHEMBL1653207 | 0.70 | HCRTR2 (0.72) | HCRTR2HCRTR1NR1I2ADRA2BKCNH2 | |
| SCHEMBL8056064 | 0.70 | HCRTR1 (0.62) | HCRTR2HCRTR1 | |
| SCHEMBL16648804 | 0.69 | HCRTR2 (0.54) | HCRTR2HCRTR1 | |
| SCHEMBL16867193 | 0.69 | HCRTR2 (0.54) | HCRTR2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2089382-A1 | SUBSTITUTED DIAZEPAN COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2009-08-19 | — | — | EP | disclosed |
| WO-2008069997-A1 | SUBSTITUTED DIAZEPAN COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-06-12 | — | — | WO | disclosed |